SCHEMBL15524532

SCHEMBL15524532

CC(C)(C)OC(=O)N(CCO)Cc1ccc(Nc2ncc(C(F)(F)F)c(C(CC(N)=O)Cc3ccccc3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT4 P35916 4/20 0.39
▸ PTK2 Q05397 10/20 0.39
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C8 P10632 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ NPR3 P17342 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ POLB P06746 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ GSK3A P49840 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ CDC7 O00311 1/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ MAP4K4 O95819 1/20 0.37
▸ PIM1 P11309 1/20 0.37
▸ PRKACA P17612 1/20 0.37
▸ CDK7 P50613 1/20 0.37
▸ CDK9 P50750 1/20 0.37
▸ HIPK2 Q9H2X6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15524665 0.92 GSK3A (0.40) PTK2POLBGAAMAPTGSK3A
SCHEMBL15524585 0.83 PTK2 (0.45) FLT4PTK2CYP3A4CYP2C8CYP2C9
SCHEMBL15524373 0.80 PTK2 (0.43) FLT4PTK2GSK3AGSK3BCDK1
SCHEMBL15524530 0.80 PTK2 (0.61) PTK2
SCHEMBL15524415 0.79 CNR2 (0.48) PTK2GSK3AGSK3BCDC7ROCK2
SCHEMBL15524522 0.78 CCNA2 (0.51) FLT4PTK2GSK3AGSK3BCDK9
SCHEMBL15524110 0.78 PTK2 (0.46) FLT4PTK2KDR
SCHEMBL15524505 0.78 PTK2 (0.52) FLT4PTK2
SCHEMBL15524495 0.77 FLT4 (0.48) FLT4PTK2GSK3AGSK3BCDC7
SCHEMBL14577154 0.77 PTK2 (0.52) FLT4PTK2STAT6KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9266864-B2 VEGFR3 inhibitors CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2016-02-23 — — US disclosed
US-20150225377-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2015-08-13 — — US disclosed
US-20140080798-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2014-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225377-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR FLT4 1/4885PTK2 240/4885CYP3A4 2375/4885
US-20140080798-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR FLT4 1/4885PTK2 260/4885CYP3A4 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback